By Gina Shaw
Four major new studies will assess the comparative effectiveness of several therapies used to treat multiple sclerosis (MS) or its symptoms, supported by a total of $19.6 million in funding from the Patient-Centered Outcomes Research Institute (PCORI).
The awards, announced on July 19, will include two studies that will compare the benefits and harms of various disease-modifying therapies (DMTs); a third will evaluate the effectiveness of medications used to treat fatigue; and the